The epidemiology and economic burden of clostridium difficile infection in Korea

Hyung Yun Choi, So Youn Park, Young Ae Kim, Tai Young Yoon, Joong Myung Choi, Bong Keun Choe, So Hee Ahn, Seok-Jun Yoon, Ye Rin Lee, In Hwan Oh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The prevalence of Clostridium difficile infection and the associated burden have recently increased in many countries. While the main risk factors for C. difficile infection include old age and antibiotic use, the prevalence of this infection is increasing in low-risk groups. These trends highlight the need for research on C. difficile infection. This study pointed out the prevalence and economic burden of C. difficile infection and uses the representative national data which is primarily from the database of the Korean Health Insurance Review and Assessment Service, for 2008-2011. The annual economic cost was measured using a prevalence approach, which sums the costs incurred to treat C. difficile infection. C. difficile infection prevalence was estimated to have increased from 1.43 per 100,000 in 2008 to 5.06 per 100,000 in 2011. Moreover, mortality increased from 69 cases in 2008 to 172 in 2011. The economic cost increased concurrently, from $2.4 million in 2008 to $7.6 million, $10.5 million, and $15.8 million in 2009, 2010, and 2011, respectively. The increasing economic burden of C. difficile infection over the course of the study period emphasizes the need for intervention to minimize the burden of a preventable illness like C. difficile infection.

Original languageEnglish
Article number510386
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Clostridium Infections
Clostridium
Epidemiology
Clostridium difficile
Korea
Economics
Health insurance
Costs
Costs and Cost Analysis
Anti-Bacterial Agents
Health Insurance
Databases
Mortality

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Choi, H. Y., Park, S. Y., Kim, Y. A., Yoon, T. Y., Choi, J. M., Choe, B. K., ... Oh, I. H. (2015). The epidemiology and economic burden of clostridium difficile infection in Korea. BioMed Research International, 2015, [510386]. https://doi.org/10.1155/2015/510386

The epidemiology and economic burden of clostridium difficile infection in Korea. / Choi, Hyung Yun; Park, So Youn; Kim, Young Ae; Yoon, Tai Young; Choi, Joong Myung; Choe, Bong Keun; Ahn, So Hee; Yoon, Seok-Jun; Lee, Ye Rin; Oh, In Hwan.

In: BioMed Research International, Vol. 2015, 510386, 01.01.2015.

Research output: Contribution to journalArticle

Choi, HY, Park, SY, Kim, YA, Yoon, TY, Choi, JM, Choe, BK, Ahn, SH, Yoon, S-J, Lee, YR & Oh, IH 2015, 'The epidemiology and economic burden of clostridium difficile infection in Korea', BioMed Research International, vol. 2015, 510386. https://doi.org/10.1155/2015/510386
Choi, Hyung Yun ; Park, So Youn ; Kim, Young Ae ; Yoon, Tai Young ; Choi, Joong Myung ; Choe, Bong Keun ; Ahn, So Hee ; Yoon, Seok-Jun ; Lee, Ye Rin ; Oh, In Hwan. / The epidemiology and economic burden of clostridium difficile infection in Korea. In: BioMed Research International. 2015 ; Vol. 2015.
@article{d9749896a087457a936556175f789a74,
title = "The epidemiology and economic burden of clostridium difficile infection in Korea",
abstract = "The prevalence of Clostridium difficile infection and the associated burden have recently increased in many countries. While the main risk factors for C. difficile infection include old age and antibiotic use, the prevalence of this infection is increasing in low-risk groups. These trends highlight the need for research on C. difficile infection. This study pointed out the prevalence and economic burden of C. difficile infection and uses the representative national data which is primarily from the database of the Korean Health Insurance Review and Assessment Service, for 2008-2011. The annual economic cost was measured using a prevalence approach, which sums the costs incurred to treat C. difficile infection. C. difficile infection prevalence was estimated to have increased from 1.43 per 100,000 in 2008 to 5.06 per 100,000 in 2011. Moreover, mortality increased from 69 cases in 2008 to 172 in 2011. The economic cost increased concurrently, from $2.4 million in 2008 to $7.6 million, $10.5 million, and $15.8 million in 2009, 2010, and 2011, respectively. The increasing economic burden of C. difficile infection over the course of the study period emphasizes the need for intervention to minimize the burden of a preventable illness like C. difficile infection.",
author = "Choi, {Hyung Yun} and Park, {So Youn} and Kim, {Young Ae} and Yoon, {Tai Young} and Choi, {Joong Myung} and Choe, {Bong Keun} and Ahn, {So Hee} and Seok-Jun Yoon and Lee, {Ye Rin} and Oh, {In Hwan}",
year = "2015",
month = "1",
day = "1",
doi = "10.1155/2015/510386",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The epidemiology and economic burden of clostridium difficile infection in Korea

AU - Choi, Hyung Yun

AU - Park, So Youn

AU - Kim, Young Ae

AU - Yoon, Tai Young

AU - Choi, Joong Myung

AU - Choe, Bong Keun

AU - Ahn, So Hee

AU - Yoon, Seok-Jun

AU - Lee, Ye Rin

AU - Oh, In Hwan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The prevalence of Clostridium difficile infection and the associated burden have recently increased in many countries. While the main risk factors for C. difficile infection include old age and antibiotic use, the prevalence of this infection is increasing in low-risk groups. These trends highlight the need for research on C. difficile infection. This study pointed out the prevalence and economic burden of C. difficile infection and uses the representative national data which is primarily from the database of the Korean Health Insurance Review and Assessment Service, for 2008-2011. The annual economic cost was measured using a prevalence approach, which sums the costs incurred to treat C. difficile infection. C. difficile infection prevalence was estimated to have increased from 1.43 per 100,000 in 2008 to 5.06 per 100,000 in 2011. Moreover, mortality increased from 69 cases in 2008 to 172 in 2011. The economic cost increased concurrently, from $2.4 million in 2008 to $7.6 million, $10.5 million, and $15.8 million in 2009, 2010, and 2011, respectively. The increasing economic burden of C. difficile infection over the course of the study period emphasizes the need for intervention to minimize the burden of a preventable illness like C. difficile infection.

AB - The prevalence of Clostridium difficile infection and the associated burden have recently increased in many countries. While the main risk factors for C. difficile infection include old age and antibiotic use, the prevalence of this infection is increasing in low-risk groups. These trends highlight the need for research on C. difficile infection. This study pointed out the prevalence and economic burden of C. difficile infection and uses the representative national data which is primarily from the database of the Korean Health Insurance Review and Assessment Service, for 2008-2011. The annual economic cost was measured using a prevalence approach, which sums the costs incurred to treat C. difficile infection. C. difficile infection prevalence was estimated to have increased from 1.43 per 100,000 in 2008 to 5.06 per 100,000 in 2011. Moreover, mortality increased from 69 cases in 2008 to 172 in 2011. The economic cost increased concurrently, from $2.4 million in 2008 to $7.6 million, $10.5 million, and $15.8 million in 2009, 2010, and 2011, respectively. The increasing economic burden of C. difficile infection over the course of the study period emphasizes the need for intervention to minimize the burden of a preventable illness like C. difficile infection.

UR - http://www.scopus.com/inward/record.url?scp=84925310733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925310733&partnerID=8YFLogxK

U2 - 10.1155/2015/510386

DO - 10.1155/2015/510386

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 510386

ER -